diagnostic set News
-
Oncomfort launches SILVA, its new Digital Sedation™ module
Oncomfort has just launched SILVA, a new module that enriches its library of solutions for the treatment of anxiety and pain for patients undergoing a medical procedure. SILVA, which features a walk in the forest, is aimed at inducing a state of dissociation comparable to moderate or deep sedation, and is particularly suitable for populations suffering from respiratory disorders. SILVA uses a ...
By Oncomfort
-
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal ...
-
Synaptive Medical Secures FDA Clearance for Evry™
Synaptive Medical, a leader in robotic surgical visualization, announced today the company has secured clearance from the Food and Drug Administration (FDA) for its superconducting, head magnetic resonance imaging (MRI) technology, Evry™. Synaptive developed Evry to provide medical professionals with diagnostic imaging capabilities directly at the point of care in critical care settings, ...
-
Altoida to Present at Upcoming Industry Conferences
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, 10:30 – 11:30 am ET Location: ...
-
Chronus Health Raises Series A Financing
Company poised to disrupt $80 billion U.S. clinical laboratory market Chronus Health, a point-of-care diagnostics company, announced today that it has raised $22 million Series A financing led by Tarsadia Investments with participation from Monta Vista Capital, SOSV, Savantus Ventures, and an undisclosed strategic investor. While several on-site blood analyzers are already available in the ...
-
Iron Horse Diagnostics, Inc. Announces License Agreement with Global IVD Powerhouse EUROIMMUN AG for First to Market ALS Diagnostic Test
Iron Horse Dx announced today that they have signed a non-exclusive license agreement with Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) to launch the first biological diagnostic test for Amyotrophic Lateral Sclerosis (“ALS”), more commonly known as Lou Gehrig’s Disease. ALS is a progressive neurological disease with an average life span of 3-5 years from ...
By nVector
-
Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, ...
-
Alaska Airlines Partners with AZOVA to Provide Ellume COVID-19 Home Tests & Video Observation for Safe, Healthy Travel
AZOVA Inc., creator of the world’s most comprehensive digital health network for COVID-19 testing and vaccination management, and Ellume, the company to bring the first non-prescription over-the-counter COVID-19 home test to market, today announced an official partnership with Alaska Airlines to provide a convenient, at-home rapid testing solution for its passengers. The Ellume COVID-19 ...
-
Alveo Technologies Announces CE Mark for its be.well™ COVID-19 Flex Test
Alveo Technologies, Inc. (Alveo) announced today that it has received its first regulatory approval with the CE (Conformité Européenne) Mark for its be.well COVID-19 Flex Test. The be.well platform is a molecular test based on an isothermal nucleic acid amplification process, and has a real-time healthcare data application program to help accelerate time to COVID-19 treatment and ...
-
Bio-Techne’s Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana
Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI) test for men. Humana is the nation’s largest Medicare Advantage provider serving an estimated 20 million patients in the United States. The EPI test is a urine-based, genomic test that helps inform ...
-
Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings
Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing. Since 2019, the two companies ...
-
How portable diagnostic readers are changing the future for patient care
There are numerous ways to provide quality diagnosis and preventative care. One of them is by investing in portable scanners, adopting huge benefits for improved healthcare procedures. What is a portable diagnostic reader? Usually a handheld device, measuring health parameters and helping to diagnose a patient using smart algorithms from a chosen assay. At AgPlus, The Agilis Reader works in ...
-
Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in ...
-
DiamiR Receives Award from Alzheimer`s Drug Discovery Foundation to Accelerate Development of microRNA Biomarkers for Alzheimer`s Disease
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today a $492,000 award in support of the project entitled "Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration." The award will accelerate the development of DiamiR's targeted diagnostic technology for detection and prediction of Alzheimer's disease ...
By DiamiR
-
Alveo Technologies’ be.well COVID-19 Test Wins XPRIZE Rapid Covid Testing Competition
Alveo Technologies, Inc. (Alveo) announced today that it has been named a winner of the $6M XPRIZE Rapid COVID Testing Competition for its be.well COVID-19 Test. The be.well™ platform provides individuals access to molecular testing and cloud-based analytics for rapid diagnosis and management of infectious diseases. The $6 million XPRIZE Rapid Covid Testing Competition challenged any ...
-
Oxford Brain Diagnostics establishes a research-based clinical MRI study in Japan to investigate how Cortical Disarray Measurement (CDM) analysis may support differential diagnosis and estimate disease severity in Dementia patients
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you